| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0729b244445c470818ee3f4d96f79b1b |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-573
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57438
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-573
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 |
| filingDate |
2020-08-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f5bfffab11fb28a20b6406c7a9109734
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5f1414e827391f789ec2f7204a2bb2b9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fe3c4795ef35ec6794c8bb533b0b2318
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bf247e4d6a9b04b318322b7f70842374
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dc2b29473b2d8eb72dd1ca9712232038
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1639e39cfe1d2ab4cc311322bd4d0366 |
| publicationDate |
2020-12-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-112114143-A |
| titleOfInvention |
Application of an oncogenic kinase marker in the diagnosis and treatment of liver cancer |
| abstract |
An application of an oncogenic kinase marker in the diagnosis and treatment of liver cancer. The invention discloses the application of the oncogenic kinase STK39 in the diagnosis and treatment of liver cancer. The present invention finds for the first time the difference in the expression of STK39 in normal liver tissue and liver cancer tissue. The expression level of STK39 in liver cancer tissue is significantly higher than that in normal tissue, and patients with high STK39 expression have poor prognosis, suggesting that STK39 is closely related to the occurrence, development and prognosis of liver cancer. Knockdown, knockout and inhibition of STK39 can significantly inhibit the growth and invasion of liver cancer cells, suggesting that STK39 can be used as a new target for the diagnosis and treatment of liver cancer. The kits and technologies for examining the expression of STK39 can be applied to the diagnosis and prognosis prediction of liver cancer, and therapeutic strategies such as antibodies or small molecule inhibitors targeting the oncogenic kinase STK39 are expected to be applied in the treatment of liver cancer. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113687077-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113687077-B |
| priorityDate |
2020-08-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |